T. Sørlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci, vol.98, pp.10869-10874, 2001.

C. M. Perou, T. Sørlie, M. B. Eisen, M. Van-de-rijn, S. S. Jeffrey et al., Molecular portraits of human breast tumours, Nature, vol.406, pp.747-752, 2000.

C. C. Bleul, R. C. Fuhlbrigge, J. M. Casasnovas, A. Aiuti, and T. A. Springer, A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1), J Exp Med, vol.184, pp.1101-1109, 1996.

T. Nagasawa, T. Nakajima, K. Tachibana, H. Iizasa, C. C. Bleul et al., Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/ stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin, Proc Natl Acad Sci, vol.93, pp.14726-14729, 1996.

M. Sharma, F. Afrin, R. P. Tripathi, and G. Gangenahalli, Transgene expression study of CXCR4 active mutants. Potential prospects in up-modulation of homing and engraftment efficiency of hematopoietic stem/progenitor cells, Cell Adhes Migr, vol.8, pp.384-388, 2014.

Y. R. Zou, A. H. Kottmann, M. Kuroda, I. Taniuchi, and D. R. Littman, Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development, Nature, vol.393, pp.595-599, 1998.

S. K. Gupta, P. G. Lysko, K. Pillarisetti, E. Ohlstein, and J. M. Stadel, Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines, J Biol Chem, vol.273, pp.4282-4287, 1998.

T. Hori, H. Sakaida, A. Sato, T. Nakajima, H. Shida et al., Detection and delineation of CXCR-4 (fusin) as an entry and fusion cofactor for T-tropic [correction of T cell-tropic] HIV-1 by three different monoclonal antibodies, J Immunol Baltim Md, vol.160, pp.180-188, 19501998.

C. Murdoch, P. N. Monk, and A. Finn, Functional expression of chemokine receptor CXCR4 on human epithelial cells, Immunology, vol.98, pp.36-41, 1999.

F. Balkwill, The significance of cancer cell expression of the chemokine receptor CXCR4, Semin Cancer Biol, vol.14, pp.171-179, 2004.

J. A. Burger and T. J. Kipps, CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment, Blood, vol.107, pp.1761-1767, 2006.

A. Zlotnik, Chemokines and cancer, Int Cancer, vol.119, pp.2026-2029, 2006.

T. Xu, H. Shen, L. Liu, and Y. Shu, The impact of chemokine receptor CXCR4 on breast cancer prognosis: a meta-analysis, Cancer Epidemiol, vol.37, pp.725-731, 2013.

Z. Zhang, C. Ni, W. Chen, P. Wu, Z. Wang et al., Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis, BMC Cancer, vol.14, p.49, 2014.

X. Ling, E. Spaeth, Y. Chen, Y. Shi, W. Zhang et al., The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo, PloS One, vol.8, p.58426, 2013.

M. Smith, K. E. Luker, J. R. Garbow, J. L. Prior, J. E. Piwnica-worms et al., CXCR4 regulates growth of both primary and metastatic breast cancer, Cancer Res, vol.64, pp.8604-8612, 2004.

S. Liang, X. Peng, X. Li, P. Yang, L. Xie et al., Silencing of CXCR4 sensitizes triplenegative breast cancer cells to cisplatin, Oncotarget, vol.6, pp.1020-1030, 2015.

A. Müller, B. Homey, H. Soto, N. Ge, D. Catron et al., Involvement of chemokine receptors in breast cancer metastasis, Nature, vol.410, pp.50-56, 2001.

E. H. Huang, B. Singh, M. Cristofanilli, J. Gelovani, C. Wei et al., A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer, J Surg Res, vol.155, pp.231-236, 2009.

A. Toullec, D. Gerald, G. Despouy, B. Bourachot, M. Cardon et al., Oxidative stress promotes myofibroblast differentiation and tumour spreading, EMBO Mol Med, vol.2, pp.211-230, 2010.

M. Darash-yahana, E. Pikarsky, R. Abramovitch, E. Zeira, B. Pal et al., Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis, FASEB J Off Publ Fed Am Soc Exp Biol, vol.18, pp.1240-1242, 2004.

A. Orimo, P. B. Gupta, D. C. Sgroi, F. Arenzana-seisdedos, T. Delaunay et al., Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, Cell, vol.121, pp.335-348, 2005.

B. Singh, K. R. Cook, C. Martin, E. H. Huang, K. Mosalpuria et al., Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer, Clin Exp Metastasis, vol.27, pp.233-240, 2010.

A. Costa, A. Scholer-dahirel, and F. Mechta-grigoriou, The role of reactive oxygen species and metabolism on cancer cells and their microenvironment, Semin Cancer Biol, vol.25, pp.23-32, 2014.

S. Liekens, D. Schols, and S. Hatse, CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization, Curr Pharm Des, vol.16, pp.3903-3920, 2010.

O. Salvucci, A. Bouchard, A. Baccarelli, J. Deschênes, G. Sauter et al., The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study, Breast Cancer Res Treat, vol.97, pp.275-283, 2006.

S. Hassan, M. Buchanan, K. Jahan, A. Aguilar-mahecha, L. Gaboury et al., CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model, Int J Cancer, vol.129, pp.225-232, 2011.

Z. Liang, H. Wu, S. Reddy, A. Zhu, S. Wang et al., Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA, Biochem Biophys Res Commun, vol.363, pp.542-546, 2007.

E. Marangoni, A. Vincent-salomon, N. Auger, A. Degeorges, F. Assayag et al., A new model of patient tumor-derived breast cancer xenograft for preclinical assays, Clin Cancer Res Off J Am Assoc Cancer Res, vol.13, pp.3989-3998, 2007.

F. Reyal, C. Guyader, C. Decraene, C. Lucchesi, N. Auger et al., Molecular profiling of patient-derived breast cancer xenografts, Breast Cancer Res, vol.14, p.11, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00675301

J. O. Trent, Z. Wang, J. L. Murray, W. Shao, H. Tamamura et al., Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists, J Biol Chem, vol.278, pp.47136-47144, 2003.

W. Zhang, J. Navenot, B. Haribabu, H. Tamamura, K. Hiramatu et al., A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists, J Biol Chem, vol.277, pp.24515-24521, 2002.

V. De-falco, V. Guarino, E. Avilla, M. D. Castellone, P. Salerno et al., Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer, Cancer Res, vol.67, pp.11821-11829, 2007.

H. Tamamura, A. Hori, N. Kanzaki, K. Hiramatsu, M. Mizumoto et al., T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer, FEBS Lett, vol.550, pp.79-83, 2003.

L. V. Rhodes, J. W. Antoon, S. E. Muir, S. Elliott, B. S. Beckman et al., Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk, Mol Cancer, vol.9, p.295, 2010.

T. Ara, M. Itoi, K. Kawabata, T. Egawa, K. Tokoyoda et al., A role of CXC chemokine ligand 12/stromal cell-derived factor-1/pre-B cell growth stimulating factor and its receptor CXCR4 in fetal and adult T cell development in vivo, J Immunol Baltim Md, vol.170, pp.4649-4655, 1950.

A. Peled, I. Petit, O. Kollet, M. Magid, T. Ponomaryov et al., Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4, Science, vol.283, pp.845-848, 1999.

F. Dommange, G. Cartron, C. Espanel, N. Gallay, J. Domenech et al., CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia, FASEB J Off Publ Fed Am Soc Exp Biol, vol.20, pp.1913-1915, 2006.

A. Carion, L. Benboubker, O. Hérault, F. Roingeard, M. Degenne et al., Stromal-derived factor 1 and matrix metalloproteinase 9 levels in bone marrow and peripheral blood of patients mobilized by granulocyte colony-stimulating factor and chemotherapy. Relationship with mobilizing capacity of haematopoietic progenitor cells, Br J Haematol, vol.122, pp.918-926, 2003.

H. E. Broxmeyer, C. M. Orschell, D. W. Clapp, G. Hangoc, S. Cooper et al., Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist, J Exp Med, vol.201, pp.1307-1318, 2005.

M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac et al., Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, pp.4265-4274, 2005.

D. J. Slamon, B. Leyland-jones, S. Shak, H. Fuchs, V. Paton et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, vol.344, pp.783-792, 2001.

K. Berns, H. M. Horlings, B. T. Hennessy, M. Madiredjo, E. M. Hijmans et al., A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer, Cancer Cell, vol.12, pp.395-402, 2007.

S. Nafi, D. Generali, G. Kramer-marek, M. Gijsen, C. Strina et al., Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer, Oncotarget, vol.5, pp.5934-5949, 2014.

R. Sáez, M. A. Molina, E. E. Ramsey, F. Rojo, E. J. Keenan et al., p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.12, pp.424-431, 2006.

B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, pp.2750-2767, 2011.

M. Allinen, R. Beroukhim, L. Cai, C. Brennan, J. Lahti-domenici et al., Molecular characterization of the tumor microenvironment in breast cancer, Cancer Cell, vol.6, pp.17-32, 2004.

B. C. Schmid, M. Rudas, G. A. Rezniczek, S. Leodolter, and R. Zeillinger, CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia, Breast Cancer Res Treat, vol.84, pp.247-250, 2004.

H. Kang, G. Watkins, C. Parr, D. , A. Mansel et al., Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer, Breast Cancer Res, vol.7, pp.402-410, 2005.

N. Cabioglu, J. Summy, C. Miller, N. U. Parikh, A. A. Sahin et al., CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation, Cancer Res, vol.65, pp.6493-6497, 2005.

Y. M. Li, Y. Pan, Y. Wei, X. Cheng, B. P. Zhou et al., Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis, Cancer Cell, vol.6, pp.459-469, 2004.

Z. Liang, Y. Yoon, J. Votaw, M. M. Goodman, L. Williams et al., Silencing of CXCR4 blocks breast cancer metastasis, Cancer Res, vol.65, pp.967-971, 2005.

C. Yazhou, S. Wenlv, Z. Weidong, and W. Licun, Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast, Tumour Biol J Int Soc Oncodevelopmental Biol Med, vol.25, pp.290-295, 2004.

J. A. Joyce and J. W. Pollard, Microenvironmental regulation of metastasis, Nat Rev Cancer, vol.9, pp.239-252, 2009.

S. Lefort, C. Joffre, Y. Kieffer, A. Givel, B. Bourachot et al., Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers, Autophagy, vol.10, pp.2122-2142, 2014.

T. Gruosso, C. Garnier, S. Abelanet, Y. Kieffer, V. Lemesre et al., MAP3K8/ TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in highgrade serous ovarian carcinomas, Nat Commun, vol.6, p.8583, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02437815